{"paper_id":"309fda1b-b914-4951-b15d-c0194a526c8e","body_text":"Gene Technology\n1\nGene Technol, Vol.9 Iss.2 No:153\nOPEN ACCESS Freely available online\nResearch Article\nCorrespondence to: Rana M, Department of Forensic Science, Amity University, Uttar Pradesh, India, E-mail: Rana.manisha1493@gmail.com \nReceived: July 17, 2020; Accepted:  July 31, 2020; Published: August 07, 2020\nCitation: Datta S, Rana M (2020) Researching Novel Variants in Endometriosis Using Next Generation Sequencing Variant Analysis. 9:153. DOI: \n10.35248/2329-6682.20.9.153.\nCopyright: © 2020 Datta S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which \npermits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.\nResearching Novel Variants in Endometriosis using Next Generation \nSequencing Variant Analysis\nShambo Datta    \n1\n, Manisha Rana\n2*\n1\nDepartment of Chemistry, University of Lyon, Lyon, France; \n2\nDepartment of Forensic Science, Amity University, Uttar Pradesh, India\nABSTRACT\nEndometriosis is characterized as the presence of ectopic endometrial tissue outside of the uterine, most generally \nin the ovaries and peritoneum. It is an illness that is impacted by various elements. It is additionally a typical \ngynaecological confusion and influences roughly 10-15% of all women of regenerative age. Later molecular and \npathological examinations demonstrate that endometriosis may fill in as an antecedent of ovarian malignant growth \n(endometriosis associated ovarian disease, EAOC), especially endometrioid furthermore, clear cell ovarian malignant \ngrowths. Albeit histological and epidemiological investigations have shown that endometriosis has a malignant \npotential, the molecular component that underlies the harmful change of endometriosis is as yet questionable, \nand the exact component of carcinogenesis must be completely illustrated. At present, the advancement and \nimprovement of another sequencing innovation, next-generation sequencing (NGS), has been progressively \nsignificant in malignant growth genomics examine. Lately, NGS has likewise been used in clinical oncology to \npropel the customized treatment of malignancy. Also, the affectability, speed, and cost make NGS a profoundly \nalluring stage contrasted with other sequencing modalities. Thus, NGS may lead to the recognizable proof of driver \nmutations and fundamental pathways related with EAOC. Our sole motivation behind the study was to decipher \nnew variants if any and report any unreported variants identified with genes. We have performed a variant analysis \ninvestigation with the assistance of Next Generation Sequencing GALAXY device accessible on the web.\nKeywords: Endometriosis; Next Generation Sequencing; Variant analysis; Novel variants \nINTRODUCTION\nEndometriosis (E) is benign gynaecological condition, debilitating, \nestrogens-subordinate, progesterone-safe, inflammatory issue \nrelated with pelvic pain and infertility, with endometrial (uterine \ncovering)-like tissue present outside the uterus (Giudice). By \nretrograde menstruation, endometrial tissue cells are transplanted \nto the pelvis (Sampson) where they set up a blood supply, react to \ncyclic hormones, develop, attack encompassing structures, progress \ntoward becoming innervated (Berkley, et al.; Tokushige, et al.), and \ninspire a nearby inflammatory reaction and scarring (Giudice LC) \n[1,2]. \nEndometriosis influences 5%–10% of regenerative age women \n(Eskenazi and Warner) [3] and half of women with pelvic pain \nas well as infertility (>100 million women around the world) \n(Meuleman et al.) [4] and is a noteworthy reason for inability and \nbargained personal satisfaction (Sasson and Taylor; Anglesio, et \nal.) [5-7]. Pelvic, lower stomach and back pain, and urinary and \ngastrointestinal indications make diagnosis challenging, on the \ngrounds that numerous indications are nonspecific or are related \nwith different disorders (Giudice) [8]. Pelvic inflammation and \nnerve invasion result in pain (Berkley, et al.; Tokushige, et al.) [9,10], \nand infertility is expected to ovulatory dysfunction, poor egg quality, \nunusual (progesterone-safe) uterine endometrium, and bargained \nembryo implantation (Giudice; Bulun SE) [1,8,11]. The meaning of \nendometriosis is histological and requires the distinguishing proof \nof the presence of endometrial organ and stroma-like tissue outside \nthe uterus (Sourial) [12]. A few hypotheses have shown that the \nhistogenesis of endometriosis is that emanating streams retrograde \nthrough the lumen of the fallopian tubes into the pelvic-peritoneal \ndepressions at feminine cycle (Robboy and Bean; Robboy, et al.) \n[13,14].\nMoreover, it can create distant foci through expansion, connection, \nand intrusion of endometrial glandular epithelial tissue to distant \norgans (Somigliana, et al.) [15]. The most normally influenced \nparts of the body incorporate the ovaries, fallopian tubes, bladder, \nrectosigmoid colon, and myometrium (Giudice; Pavone and Lyttle) \n[1,16]. Another hypothesis, the coelomic metaplasia hypothesis, \nrecommends that endometriosis emerges from the metaplasia of \ncells that line the instinctive and stomach peritoneum following \n\n2\nDatta S, et al.\nOPEN ACCESS Freely available online\nGene Technol, Vol.9 Iss.2 No:153\nappeared to be imperative in a few hormone-responsive malignant \ngrowths (Rae; Ghosh) [36,37]. Another GWAS on 2,109 instances \nof endometriosis in 2013 performed by Albertsen et al additionally \ndemonstrated that SNPs related with WNT4 were related with the \ndevelopment of endometriosis (Albertsen, et al.) [38], affirming \nresults recently observed by Uno et al in 2010 (Uno, et al.) and \nPainter et al in 2011 (Painter) [39,40]. An ongoing GWAS meta-\ninvestigation by Uimari, et al [41] showed certain cellular control \npathways which were enhanced in endometriosis; MAPK-related \npathways controlling cell survival, movement, division, and gene \nexpression, also pathways associated with extracellular matrix \nstructure (Uimari O et al.) [41]. Likewise in 2017, Sapkota et al \ndistinguished five novel loci in sex steroid hormone pathways \nrelated with endometriosis hazard (FN1, CCDC170, ESR1, SYNE1 \nand FSHB) (Sapkota Y, et al.) [42]. While GWAS information \ncan give knowledge into genomic abnormalities that incline to \nendometriosis, further hereditary and useful examination is vital \nso as to completely comprehend the basic mechanisms responsible \nof the disease phenotype (Fung) [43].\nDisease characteristics and clinical overview\nThe clinical determination of endometriosis is challenging, \nas signs and side effects may differ significantly and there is an \nabsence of reliable indicative serum biomarkers (Berker and \nSeval) [44]. Raised dimensions of the biomarker CA-125 are not \nexplicit since they can show the presence of different gynaecologic \npathologies, for example, endometriosis, ovarian malignancies or \nirritation (Moss, et al.)  [45]. Now and again, dimensions of the \nserum biomarker HE4 can be utilized to recognize endometriosis \nfrom ovarian and endometrial malignancies (Huhtinen, et al.) \n[46]. In numerous patients, endometriosis is clinically presumed \ndependent on history and examination, and treated experimentally \nwith hormonal treatment (e.g. estrogen-progestin contraceptives or \nprogestin-only treatments) without medical procedure (Leyland, et \nal.) [47]. A reliable indicative serum biomarker would speak to a \nnoteworthy development for clinically diagnosing endometriosis \n(Berker and Seval) [44].\nMedical procedure with histological affirmation of ectopic \nendometrial organs and stroma remains the best standard for \ndetermination (Mykes, et al.; Hori and Committee) [48,49]. \nMedical procedure is commonly held for patients who fail \nmedicinal treatment, or who want pregnancy, and is generally \nperformed by laparoscopy (Burney and Giudice, 2012; Eskenazi \nand Warner; Rogers, et al.; Burghaus, et al.; Wykes, et al.) [3,50-\n53]. Gonadotropin-discharging hormone agonists are additionally \nutilized in serious cases. Other potential treatment alternatives \nincorporate hormone receptor (estrogen or progesterone) \nmodulators, invulnerable modulators, aromatase inhibitors, \nand against angiogenic drugs (Bedaiwy, et al.; Streuli, et al.) \n[54,55]. There are various brilliant clinical surveys distributed \non endometriosis. There are three subtypes of endometriosis \nportrayed in patients that can be clinically distinguished: \novarian endometriosis (endometriomas), superficial peritoneal \nendometriosis, and deep infiltrating endometriosis. Endometriotic \nsores have been appeared to have modified estrogen biosynthesis \nand are estrogen subordinate. Estrogen dysregulation gives off an \nimpression of being connected to expanded aromatase articulation \nand action (Bukulmez, et al.) [56]. Also, protection from the \ncounter proliferative impacts of progesterone is related with a move \nin estrogen receptor isoform articulation bringing about estrogen-\nintervened restraint of progesterone receptor articulation (Han \nhormonal, ecological, or irresistible incitement (Overton, et al.) \n[17]. A later hypothesis underpins stem/ progenitor cells and bone \nmarrow-determined immature microorganisms in the pathogenesis \nof endometriosis (Sasson and Taylor) [5]. Notwithstanding, \nAnglesio. recognized substantial malignant growth driver \nmutations in the glandular epithelium of deep infiltrating \nendometriosis sores, and the authors recommended that the \nundifferentiated cell related hypothesis requires extra investigations \nto affirm the rational of a speculation (Anglesio, et al.)  [7]. \nAdditionally, (Noe, et al.) recognized 19 mutations enhanced in \nepithelial however not in stromal sores utilizing bead advanced \nPCR innovation [18]. The authors proposed another theory that \nepithelial and stromal segments in creating endometriotic sores \nco-create from independent ancestors. As right on time as 1925, \nSampson proposed a potential relationship among's endometriosis \nand malignant change (Sampson) [19]. Czernobilsky and Morris \nportrayed a \"middle stage\" in the harmful change alluded to as \n\"atypical endometriosis\"; it is as of now characterized by the level \nof dysplastic histologic atypia (Czernobilsky and Morris) [20]. \nQuite, endometriosis is viewed as a potential pre-intrusive sore \nand is as of now named a tumor-like sore under the World Health \nOrganization (WHO) histologic arrangement of ovarian tumors. \nLately, Tsai et al. (Tai et al.) [21] demonstrated that patients with \npelvic incendiary ailment had a three-fold increment in the danger \nof creating endometriosis dependent on the National Health \nInsurance Research Database (NHIRD) of Taiwan. The hidden \nmechanism of endometrisis might be related with three unique \nprocedures:\nEndometriosis pieces move from the uterus through the fallopian \ntubes amid retrograde feminine cycle, spreading these endometriosis \nsections to the peritoneal depression and embedding on the serosal \nsurface. Metaplasia of the coelom and Vascular and lymphatic \nmetastatic spread (Sasson and Taylor; Anglesio; Bulun; Sampson; \nSampson; Figueira) [5,6,11,19,22].\nRisk factors and Etiology of endometriosis \nHuge hazard factors for the development of endometriosis \nincorporate conditions that increase the odds of retrograde \nmenstruation and hereditary/genetic factors. Hazard factors for \nendometriosis incorporate early menarche, nulliparity, broken \nuterine bleeding, variant estrogen levels (Darrow; Signorello, et al.; \nCramer, et al.; Candiani, et al.), and low weight record (Signorello, \net al.) [23-26]. Factors, for example, sufficient exercise might be \nprecaution against development of endometriosis (Kvaskoff) [27]. \nIt is realized that the occurrence of endometriosis in women with \nfirst-degree relatives who likewise have the ailment might be up \nto multiple times higher than that of the all inclusive population \n(Matalliotakis; Treloar) [28,29]. There is probably going to be \na multifactorial hereditary inclination for endometriosis, and \ngenome-wide association studies (GWAS) have shown single-\nnucleotide polymorphism (SNP) profiles which may expand the \ndanger of endometriosis in people (Rahmioglu) [30]. In 2012, \nNyholt et al (Nyholt, et al. 2012] [31] distinguished 18 genomic \nareas harboring 38 putative endometriosis-related SNPs in a GWAS \nincluding 4,604 instances of endometriosis.\nAmong the huge aberrations distinguished were SNPs related \nwith the WNT4 gene, known to be critical in reproductive \ntract differentiation and advancement in mammalian females \n(Jaaskelainen; Vainio et al.) [32,33] just as steroidigenesis (Boyer \nA et al.) [34], VEZT, appeared to be down regulated in gastric \ndiseases (Guo X et al.) [35], and GREB1, an estrogen-managed gene \n\n3\nDatta S, et al.\nOPEN ACCESS Freely available online\nGene Technol, Vol.9 Iss.2 No:153\nand O’Malley, et al.) [57]. Moreover, epigenetic changes identified \nwith modifications in hormonal flagging pathways have likewise \nbeen accounted for (Guo, et al.) [58]. Notwithstanding irregular \ncharacteristics in hormone control, oxidative stress brought about \nby high iron levels has been accounted for to prompt expanded levels \nof somatic mutations (Kobayashi, et al.) [59]. Vercellini's 'relentless \nmenstruation theory's (Vercellini, et al.) [60] refers to retrograde \ntransport of blood, endometrial tissue, and cancer-causing agents \nas conceivably prompting the beginning of both endometriosis, as \nwell as serous, endometrioid, and clear cell ovarian tumors. Large \namounts of oxidative stress and iron exposure are the result of the \ninflammatory reaction that may emerge from either retrograde \nfeminine cycle or the endometriosis itself. Oxidative stress prompts \nexpanded angiogenesis, endometriosis expansion, and specific iron-\ninterceded DNA harm prompting potential oncogene mutations \n(Toyokuni, et al.) [61]. Nearby and fundamental inflammatory \nreactions likely assume a key job in the reason for unending pain \nand infertility (Ota, et al.; Lin, et al.; Ahn, et al.; Zhang, et al.; \nMcKinnon, et al.) [62-66]. In this way, inflammatory reactions, \nalongside the known hormonal dysregulation in endometriotic \ninserts, may drive carcinogenesis (Worley, et al.) [67]. While \nsome EAOCs emerge with clearly related endometriosis, this \nisn't generally the situation. Curiously, numerous EAOC need \nrecognizable endometriotic antecedent sores as they might be \nannihilated by the subsequent EAOC or just not identified because \nof testing constraints.\nEndometriosis-associated ovarian cancer\nEndometriosis is related with 15%-half of clear-cell and \nendometrioid ovarian tumors, and there is a two-to three-fold \nincrement in ovarian malignancy in people with endometriosis \n(Brinton, et al.; Rossing, et al.; Forte, et al.) [68-70]. Endometriosis-\nassociated ovarian disease (EAOC) might be created through \nvarious components contrasted with non-endometriosis related \novarian malignancy. Also, EAOC introduces at a prior stage and \nwith lower-grade sores than non-EAOC. Till date, numerous \nexaminations, including deliberate reviews (Nezhat, et al.; Kvaskoff, \net al.) [71,72] and meta-investigations (Somigliana E, et al.; Pearce, \net al.) [15,73], have shown that women with endometriosis may \nhave an expanded danger of epithelial ovarian cancer (EOC). \nBesides, another investigation bolsters the idea that endometriosis \nis a malignant change and that the histogenesis of endometriosis \nsubject to a few components, including hereditary modifications, \nhormonal, and immunological variables (Pavone and Lyttle) [16]. \nLately, Matalliotakis (Matalliotakis, et al.) [74] distinguished 20 \ninstances of endometriosis associated ovarian malignant growth in \n1,000 ladies with endometriosis, among which endometrioid disease \n(60%) was the most continuous, trailed by clear cell carcinoma \n(20%) and serous and mucinous adenocarcinomas (20%). Also, \nKok et al. (Kok, et al. 2015) [75] showed that ovarian endometriosis \nis related with a 4-fold expanded danger of ovarian malignancy. \nMolecular evidence recommends that clear cell carcinoma (CCC) \nand endometrioid ovarian cancer (ENOC) emerge specifically \nfrom endometriotic sores. Very recently, a few complete survey \narticles concentrated on the endometriosis and EAOC (Bulun; \nDawson, et al.; Oda, et al.; Anglesio and Yong; Zondervan, et al.) \n[6,11,76-78] and have featured ongoing updates and advance in the \npathogenesis of endometriosis and EAOC dependent on clinical, \ngenomic, and immunological viewpoints. However, the molecylar \ncomponent that underlies the malignant change of endometriosis \nstays disputable, and the exact component of carcinogenesis has \nnot yet been elucidated. The various elements detailed in the \npathogenesis of endometriosis-related ovarian malignancy are \noutlined in (Figure 1).\nDevelopment of EAOC from endometriosis \nThe idea that endometriosis is the forerunner lesion of some \novarian malignant growth subtypes has been upheld by various \nlines of examination. The affiliation was noted by pathological \ntechniques, however epidemiological, and hereditary examinations \nhave been important (Sampson, et al.; Sampson, et al.; Vercellini.; \nLaGrenade and Silverberg, et al.; Fukunaga, et al.; Pearce, et al.; \nJiang, et al.; Scott; Lu, et al.; Prowse, et al.; McMeekin, et al.; Sainz \nde la Cuesta, et al.) [73,79,80-88]. Jiang et al depicted a portion \nof the principal contemplates recommending a molecular basis \nconnecting endometriosis with cancer development in 1998. \nThey exhibited a similar loss of heterozygosity (LOH) occasions \nin endometriosis lesion and contiguous endometrioid ovarian \nmalignant growths in 82% of cases inspected (n=11) (Jiang, et al.) \n[83]. Comparable proof was accounted for by Prowse et al in 2006, \nwho exhibited normal LOH occasions in both endometrioid and \nclear cell OCs and their related endometriosis lesion, including \nboth nearby and contralateral endometriosis (Prowse, et al.) [86]. \nMoreover, LOH bringing about PTEN loss might be an early \ndriver occasion in the beginning of in EAOC from endometriosis \n(Worley, et al.; Sato, et al.) [89,90]. Throughout the most recent 7 \nyears, sequencing and immunohistochemical research have given \ncorroborative proof that changes found in endometriosis-related \nmalignant growths are found in adjoining endometriosis. These \nsequencing examines unmistakably exhibit a clonal connection \namong benign and malignant partners affirming that the malignant \ngrowths have actuality emerged from the endometriotic lesions \n(Stamp, et al.; Anglesio, et al.; Wiegand, et al.; Chene, et al.) [91-\n94]. Somatic mutations and other genomic deviations are found \nin endometriosis that have been embroiled in the advancement \nof cancer. Mutations in TP53 (Bischoff, et al.; Sainz de la Cuesta, \net al.) [95,96] KRAS (Anglesio, et al.; Vestergaard, et al.) \n[7,97], PTEN (Sato, et al.), PIK3CA (Laudanski, et al.; Yamamoto, \net al.) [98,99], and ARID1A gene locales (Anglesio, et al.) have \nbeen portrayed. Loss of expression of mismatch repair proteins \n(Grassi, et al.)  [100], microsatellite precariousness (Fuseya, et \nal.) [101], and tissue-explicit gene copy number changes (Yang, et \nal. 2013; Mafra, et al.)  [102,103], may likewise be found in \nendometriosis sores. LOH in endometriosis at known oncogenic \nloci is additionally habitually observed (Sato, et al.; Ali-Fehmi, et \nal.; Xu, et al.; Obata and Hoshiai, et al.; Thomas and Campbell, \net al.; Jiang, et al.; Silveira, et al.) [83,90,104-108]. SNPs that are \nrelated with oncogenic change (seen in GWAS datasets) have \nFigure 1: Pathogenesis of EAOC.\n\n4\nDatta S, et al.\nOPEN ACCESS Freely available online\nGene Technol, Vol.9 Iss.2 No:153\nbeen recognized in instances of endometriosis (Nyholt, et al.; \nAlbertsen, et al.; Uno, et al.; Painter, et al.) [31,38-40]. In 2015, a \nmeta-investigation detailed by Lee et al including more than 15,000 \novarian disease patients, assessed the 38 putative endometriosis-\nrelated SNPs distinguished by Nyholt in 2012 (Nyholt, et al.). Eight \nof these were related with critical hazard for ovarian malignancy \n(rs7515106, rs7521902, rs742356, rs4858692, rs1603995, \nrs4241991, rs6907340, and rs10777670) (Lee, et al.) [109]. Likewise \nin 2015, Lu et al exhibited shared hereditary hazard among \nendometriosis and epithelial ovarian malignancy, especially clear-\ncell and endometrioid histotypes utilizing genome wide affiliation \n(GWAS) datasets (Lu, et al.) [85].\nARID1A is a tumor silencer gene that was observed to be \ntransformed in an extensive number of EAOC (Wiegand, et al.) \n[93]. Examiners were initially eager to find that up to 42–61% of \nCCC and 21–33% EnOC show loss of the comparing ARID1A gene \nprotein articulation (BAF250a) on IHC (Stamp, et al.; Wiegand, \net al.; Yamamoto, et al.) [91,93,110]. ARID1A manages essential \ncelularl capacities (expansion and genomic stability) as a tumor \nsilencer gene; along these lines, it was believed that it may play a \nrole in the change of endometriosis to malignancy (Wu, et al.) [111]. \nIn 2015, Anglesio et al showed that clear cell ovarian carcinomas \nimparted numerous transformations to related simultaneous \nendometriosis sores, incorporating mutations in ARID1A. Shared \ntransformations in PIK3CA were additionally distinguished among \nendometriosis and clear-cell sores, an occasion happening in early \nmovement components in other malignant growth types (Anglesio, \net al.). This investigation unmistakably exhibited depicted \ntransformations in coterminous endometriosis shared by EAOC, \nand even some distant sores contained the equivalent (PIK3CA and \nARID1A) transformations. Studies looking at BAF250a expression \nby IHC demonstrate that in simply over half of the announced \ninstances of EAOC, loss of BAF250a expression is seen most of \nthe time (67–80%) in regions of coterminous endometriosis or \natypical endometriosis, and that lost Baf250a protein expression \nappeared to be an early molecular occasion in the advancement of \nBaf250a-negative EAOC (Stamp, et al.; Chene, et al.; Nishikimi, \net al.) [91,94,112]. Strangely, ARID1A transformations are not \nadequate all alone to cause malignancy (Guan, et al.) [113]. In help \nof this perception, Borrelli et al portrayed halfway loss of BAF250a \nin ordinary endometrium without disease (Borrelli, et al.) [114]. \nAn imperative examination lately announced that that 65% of \nmalignancy causing genomic variations are arbitrary DNA repair \nanomalies (Tomasetti and Vogelstein, et al.) [115]. Bringing this \ndata into context, one can infer that BAF250a loss in endometriosis \ncould speak to an EAOC antecedent sore; nonetheless, ARID1A \ntransformations are neither a fundamental driver transformation \nnor a critical determinant of the malignant phenotype. The \npresence of transformations in endometriosis is an indication of \nmore extensive genomic interruption prompting the advancement \nof EAOC. Figure 2 demonstrates a schematic of the foundation \nand development of endometriosis sores to EAOC. Investigations \nhave been finished looking at patient results in EAOC dependent \non the presence or absence of BAF250a expression. In view of \nthe accessible proof, it still can't seem to be resolved concerning \nwhether there are contrasts in visualization or treatment results \nidentified with BAF250a loss in EAOC (Katagiri, et al.; Lowery, et \nal.) [116,117]. There are couple of recognizable proteomic changes \nin a board of proteins assessed by reverse phase protein array \n(RPPA) recommending that BAF250a loss does not characterize a \nparticular proteomic signature (Wiegand, et al.) [118]. Moreover, \nthe presence or absence of an endometriosis antecedent sore in \nEAOC has not been related with change in overall disease result \n(Minlikeeva, et al.) [119].\nEndometriosis as neoplasm \nDeep infiltrating endometriosis is an intriguing uncommon subtype \nof endometriosis which was lately exposed to genomic assessment. \nDeep endometriosis has a penchant to locally attack encompassing \nstructures (entrail, bladder, ureter) yet seldom metastasises. \nAnglesio et al showed the presence of somatic mutation occasions \nin 79% of 24 cases, with 26% of all cases screened harbouring \nmeasurably somatic mutation in known malignant growth driver \ngenes, for example, KRAS, PIK3CA, ARID1A, and PPP2R1A. \nIn the investigation of a littler subset of tests, mutations in KRAS \nobserved to be available in the epithelial part of endometriosis \nsores were missing in the stroma. Moreover, one patient was \nfound to have the equivalent KRAS transformation in three \nspatially unmistakable endometriosis sores. While these molecular \noccasions are usually found in EAOCs, this investigation showed \ntheir essence in deep infiltrating endometriosis. While customarily \noncogenic driver transformations (like KRAS) were available in a \nquarter of tests, they didn't seem to demonstrate the probability \nof the sore to advance into a gynaecologic malignant growth nor \nhave all the earmarks of being required for the improvement of the \ndeep-infiltrating sores.\nThis recommends extra or distinctive molecular components \nmight be having an effect on everything in the improvement of \nendometriosis, and future research utilizing an expansive cluster \nof molecular advances (epigenetic, grafting deviations, complex \nchromosomal adjustments, transcriptome, proteome and post-\ntranslational changes) to examine the functional science of \nendometriosis is justified. Novel molecular innovations may \nlikewise help clarify the biology of clonally indistinguishable \nsores in a similar patient. At long last, the bizarre presence of \nendometriosis in lymph hubs has been portrayed, with a few cases \nindicating BAF250a loss (Borrelli, et al.) [114]. Consequently, one \nmay expect that these extremely irregular cases are molecularly \nparticular as they copy locally metastatic malignant growths. Maybe \neven the deep-infiltrating subtype of endometriosis, which shows \nunequivocal intrusion of encompassing tissues, might be more \nfittingly considered a neoplasm than a benign condition. Better \ncomprehension of the molecular pathology of this disease may give \nhelpful procedures to analyze and treat complex cases, with the \nobjective of decreasing morbidity and ailment inconveniences like \ninfertility.\nAdvanced technologies are revolutionizing the aspects of the \nathogenesis of endometriosis \nThe next-generation sequencing (NGS) stage will significantly affect \nFigure 2: Erythema in heliotrope.\n\n5\nDatta S, et al.\nOPEN ACCESS Freely available online\nGene Technol, Vol.9 Iss.2 No:153\ndisease diagnosis, management and treatment and anticipating \nresult and reaction (Meldrum, et al.) [120]. NGS innovation is a \nplausible and solid strategy with that might be utilized to identify \nnovel and uncommon somatic mutations. Also, NGS has been \neffectively utilized to distinguish germline and somatic mutations \nin a different of malignancies, including gynecological cancer \n(Evans, and Matuloni) [121], and it can go about as a diagnostic \ntechnique and aiding the customized treatment of malignant \ngrowth (Valtcheva, et al.) [122]. What's more, NGS innovation \nsubstantially affects precision medication and hazard assessment, \nincluding early diagnosis, prognosis, and optimization of treatment \nchoice (Morash, et al.; Fountzilas and Tsimberidou) [123,124]. By \nperforming genomic screening by means of NGS innovation, it is \nconceivable to distinguish whether a patient has previous hereditary \nconditions that would make them progressively susceptible to \ncreating malignancy in their lifetime (Meldrum, et al.) [120]. In the \nongoing years, NGS has been used to describe genomic alterations \nin EAOC. A few investigations had shown the utility of NGS in \nrecognizing driver mutations in EAOC patients utilizing whole \ngenome sequencing and target sequencing (Wiegand, et al.; Er, \net al.) [93,125]. In our past investigation, ultra-deep (>1000×) \ntarget sequencing was performed on 409 cancer related genes to \ndistinguish pathogenic changes related with EAOC, and hopeful \ngenes prescient of threatening change were recognized (Zondervan, \net al.) [78]. In light of these discoveries, the recognized driver \nmutations for benign to premalignant sores could be focuses to \ncontrol the early diagnosis and avoidance of EAOC. As recently \nexamined, endometriosis is a confusion in which the endometriotic \ntissue is outside the uterus, andit is commonly thought to be \na benign sickness. Also, we realized that NGS or ultra-deep \nsequencing empowers the revelation of novel sequence variants. \n(Li, et al.) [126] recently demonstrated that hereditary changes in \ncyto-skeletal and chromatin re-modelling proteins assume a critical \njob in the pathogenesis of endometriosis utilizing whole-exome \nsequencing. Lately, exome sequencing likewise yielded promising \ndiscoveries that sores in deep infiltrating endometriosis, which are \nrelated with for all intents and purposes no danger of malignant \ntransformation, harbor substantial malignant growth driver \nmutations (Anglesio, et al.). In spite of the fact that endometriosis \nis viewed as a benign issue, the consequences of NGS innovation \nrecommend another point of view, that the glandular epithelium \nof deep infiltrating endometriosis injuries harbor understood \nmalignant related somatic transformations. Suda K et al. (Suda, \net al.) [127] distinguished numerous malignant related somatic \ntransformations in epithelial cells from ovarian endometriosis \nand ordinary endometrium utilizing whole exome sequencing. \nThey affirmed that KRAS and PIK3CA were the most oftentimes \ntransformed genes in endometriotic and ordinary uterine \nendometrial epithelium tests utilizing target-gene sequencing. \nThey additionally showed that clonal extension of epithelial \ncells with malignant related somatic transformations prompts \nthe advancement of endometriosis. These discoveries reinforce \nthe past hypothesis that the root of endometriosis happens at \nthe genomic level. Lately, Lac, et al.) [128] distinguished physical \nsomatic driver transformations in incisional endometriosis and \nprofound invading endometriosis utilizing an overly sensitive \nmalignant growth hotspot sequencing board, incorporating \nhotspot changes in KRAS, ERBB2, PIK3CA and CTNNB1. Taken \ntogether, NGS innovation may enable us to grow our insight into \nthe pathogenesis of endometriosis and subvert the traditional \nhypothesis. These examinations have involved endometriosis as a \npotential premalignant issue and have demonstrated it might give \nchances to diagnostics and treatments sooner rather than later. In \nany case, the impact and job of malignant related transformations \nin the pathogenesis of endometriosis must be completely clarified.\nMATERIALS \nThe variant analysis was performed on study accession \nPRJNA326570 where sample SRR3711510 and SRR3711512 were \nconsidered as a control sample for rest all 8 samples (SRR3711641, \nSRR3711642, SRR3711644, SRR3711645, SRR3711646, \nSRR3711647, SRR3711648 and SRR3711649). For NGS data \nanalysis the library layout was Illumina sequenced. In the Illumina \nplatform, the raw reads produced by the sequencing machine are \nshown in FASTQ, viewed as the standard design configuration of \nsequencing reads. The prepared library for the sample is a single-\nend library.\nMETHODS \nNext-generation sequencing is an incredible asset for recognizing \nuncommon and de novo variations, disease mapping, and \nevaluating expression levels. For the investigation, NGS reads \nare first adjusted to a reference genome, and afterward exposed \nto variant calling after fundamental quality control strategies. The \nalignment is pivotal for variant calling precision, and BWA is a \nbroadly utilized aligner with great execution. Galaxy system is a \nweb open application for high-throughput genomics, uncovering \nwell known third-party data sources and standard bioinformatics \ninvestigation bundles in an incorporated and steady structure, \nintended to help scholar clients performing reproducible \nexaminations. There is a free open site (http://usegalaxy.org). To \nimport information, we utilized the ENA (European nucleotide \ndocument) governs by EMBL (website https://www.ebi.ac.uk/ena). \nWhen the file is uploaded from the ENA FASTQ Groomer (Galaxy \nTool Version 1.1.1) is performed. It changes over between different \nFASTQ quality organizations. FASTQ Groomer is open-source \ntoolset was executed in Python and has been coordinated into the \nonline data examination platform Galaxy (Goss, et al.; Nichols et \nal.) [129,130]. After grooming of the data quality check is done \nusing FASTQC tool. FastQC Read Quality reports (Galaxy Tool \nVersion 0.72) gives quality control keeps an eye on raw sequence \ndata originating from high throughput sequencing pipelines. The \nreport incorporates synopsis charts and tables in an H. T. M. L \nbased configuration. These outcomes got from QC investigations \ngive us adequate data concerning whether the data has any issues or \nnot before continuing forward. For above samples the quality was \nnot good enough to perform mapping, therefore before mapping \ntrimming is performed using TRIMMOMATIC (Galaxy Version \n0.36.5) methods. BOWTIE2 (Galaxy Tool Version 2.3.4.2) is \nutilized to list reference genome which works at rapid and memory \nproficient way. Bowtie2 is utilized for short read alignment. \nWhat makes bowtie2 fascinating is the utilization of almost no \nRAM with precision and unobtrusive execution in ordering the \nalignment (Langmead and Salzberg) [131]. The alignment results \nyield in SAM format (Li, et al.) [132] after mapping to remove PCR \nduplicates RmDup tool (Galaxy Tool Version 2.0.1) is used and \nafter removing duplicates quality is checked before proceeding. \nMpileup (Galaxy Tool Version 2.1.4) reports variants for one or \nvarious B.A.M documents. Alignments records are gathered \ngiving one log document (content organization) and other Variant \nCalling record (V.C.F format) which will give data like probability \n\n6\nDatta S, et al.\nOPEN ACCESS Freely available online\nGene Technol, Vol.9 Iss.2 No:153\ngenotype, position on reads, mapping quality (Blankenber, et al.; \nBlankenberg, Daniel, et al.; Giardine, Belinda, et al.; Goecks, \net al.; Sherry, et al.; Team The Galaxy] [133-136]. Varscan for \nvariants (Galaxy Tool Version 2.4.2) performs variant location for \nenormously parallel sequencing data, for example, exome, W.G.S, \nand transcriptome information. It calls variants from M Pileup \ndataset and produces a Variant Calling File (V.C.F) (Andrew) [137]. \nFinally, we used wANNOVAR to perform regional and functional \nannotations. Variant calls are then clarified utilizing Annovar \n(Wang, et al.) [138]. The comment incorporates the utilization of \ndatabases, for example, ClinVar, Exac, dbSNP, and dbNSFP.\nRESULT AND DISCUSSION \nThe novel variants acquired from the outcomes as appeared in \nthe Table 1 which were not recently observed associated with \nEndometriosis. We found an aggregate of 24 new variations from \nShenzhen Second Hospital (Shenzhen, Guangdong, China) \nendometrium sample. Among which, the majority of the variants \ngot were non-synonymous SNVs, aside from them just a single of \nthe variant (ADRA1B) indicated stop-gain SNP. This could be then \nadditionally considered upon for their jobs in different disease or \ncan be contrasted with different samples for same disease (Table 2). \nTable 1: Novel Variants with chromosome location and SNP\nSample No.\nNovel \nVariants \nObtained\nType Mutations in \nExonic Functions\nChromosome \nLocation\nSRR3711641 ATP6V0D2 Nonsynonymous \nSNV Chr8: 86150277\nVPS13B Nonsynonymous \nSNV\nChr8: \n99859386\nGLG1 Nonsynonymous \nSNV\nChr16: \n74493027\nSRR3711642 LTBP3 Nonsynonymous \nSNV\nChr11: \n65540877\nCLCN7 Nonsynonymous \nSNV Chr16: 1474949\nMNX1 Nonsynonymous \nSNV Chr7: 1.57E+08\nADRA1B Stopgain Mutation Chr5: 1.6E+08\nSRR3711644\nUROD Nonsynonymous \nSNV\nChr1:  \n45015374\nCLCN7 Nonsynonymous \nSNV Chr16: 1474949\nRABGEF1 Nonsynonymous \nSNV Chr7: 66805250\nSRR3711645\nASCL2 Nonsynonymous \nSNV Chr11: 2269837\nDSCAML1 Nonsynonymous \nSNV\nChr11: \n1.17E+08\nZNF274 Nonsynonymous \nSNV\nChr19: \n58211630\nPLXNA1 Nonsynonymous \nSNV Chr3: 1.27E+08\nSEMA6A Nonsynonymous \nSNV Chr5: 1.16E+08\nRABGEF1 Nonsynonymous \nSNV Chr7: 66805250\nSRR3711646\nLPR5 Nonsynonymous \nSNV\nChr11: \n68410020\nMFAP3L Nonsynonymous \nSNV Chr4: 1.7E+08\nGPR22 Nonsynonymous \nSNV Chr7: 1.07E+08\nATP6V0D2 Nonsynonymous \nSNV Chr8: 86150277\nSRR3711647\nDENND3 Nonsynonymous \nSNV Chr8: 1.41E+08\nSRR3711647\nUSP7 Nonsynonymous \nSNV Chr16: 8904506\nL3MBTL1 Nonsynonymous \nSNV\nChr20: \n43534909\nMFAP3L Nonsynonymous \nSNV Chr4: 1.7E+08\nADRA1B Stopgain Mutation Chr5: 1.6E+08\nPRICKLE4 Nonsynonymous \nSNV Chr6: 41786956\nSRR3711649\nDSCAML1 Nonsynonymous \nSNV\nChr11: \n1.17E+08\nARHGAP40 Nonsynonymous \nSNV\nChr20: \n38637795\nCEBPB Nonsynonymous \nSNV\nChr20: \n50191512\nSEMA3A Nonsynonymous \nSNV Chr7: 83961468\nVPS13B Nonsynonymous \nSNV\nChr8: \n99859386\nTable 2: The frequency for mutation of the novel variants for \nentometriosis was discovered utilizing Intogen Database (https://www.\nintogen.org/seek).\nGenes Mutation Frequencies (From \nintogen)\nVPS13B 5.65%\nPLXNA1 3.91%\nDSCAML1 2.61%\nGLG1, LRP5 1.74%\nRABGEF1, DENND3, PRICKLE4, \nSEMA3A, SEMA6A, ADRA1B 1.30%\nCLCN7, USP7, MFAP3L 0.87%\nL3MBTL1, UROD, GPR22, \nATP6V0D2, ZNF274, ARHGAP40 0.43%\nLTBP3, MNX1, CEBPB 0%\nASCL2 No Data\nThe variants involvement in endometriosis was affirmed utilizing \nDriver: A database for malignancy driver gene (driverdb.tms.\ncmu.edu.tw/ddbv2/index.php). Four of the variants acquired \nARHGAP40, UROD, MNX1 and MFAP3L were appeared to have \nsome association in endometriosis as saw on Driver. The remaining \ngenes are novel and once in a while connected with endometriosis. \nMajority of the variants obtained showed relativeness in other \ndiseases, apart from endometriosis. The molecular genetics of some \nof the novel variants is discussed:\nLRP5: Gong et al. (2001) demonstrated that LRP5 influences bone \nmass gathering during development and recognized changes in the \nLRP5 gene (e.g., 603506.0001) that develop autosomal recessive \nosteoporosis-pseudoglioma disorder (OPPG; 259770) [139]. They \nfound that obligate bearers of mutant LRP5 gene had decreased \nbone mass when contrasted with age and sexual orientation \ncoordinated controls. Little et al. (2002) recognized a gly171-to-\n\n7\nDatta S, et al.\nOPEN ACCESS Freely available online\nGene Technol, Vol.9 Iss.2 No:153\nval transformation in the LRP5 gene (G171V; 603506.0013) that \noutcomes in an autosomal prevailing high bone mass attribute (see \n601884) [140]. Boyden, et al. (2002) found the equivalent LRP5 \ntransformation in a family with autosomal dominant [141], high \nbone density related with square jaw and torus palatinus. Guo, \net al. (2006) genotyped 1,873 Caucasian people from 405 family \nunits for SNPs and haplotypes of the LRP5 gene and found that \nthe regular allele A for SNP4 (rs4988300) and the minor allele G \nfor SNP6 (rs634008) were essentially connected with obesity and \nbody mass index (BMI) [142]. Critical affiliations were additionally \nseen between the regular haplotype A-G-G-G in block 2 (intron \n1) with obesity, BMI, and fat mass (p under 0.001, p under \n0.001, and p=0.003, individually). Guo et al. (2006) inferred that \nintronic variations of the LRP5 gene are particularly connected \nwith weight. In affected people from 4 irrelevant families with \npolycystic liver disease-4 with or without kidney cysts (PCLD4; \n617875), Cnossen et al. (2014) recognized 4 diverse heterozygous \nmissense transformations in the in the LRP5 gene (603506.0035-\n603506.0038) [143]. Two transformations influenced the \nintracellular domain, and 2 influenced the extracellular domian. \nThe transformation in the main family was found by whole exome \nsequencing and affirmed by Sanger sequencing; the 3 different \ntransformations were found by direct sequencing of the LRP5 \ngene in a cohort of 150 probands with cystic liver disease. The \ntransformations isolated with the turmoil in the families, with \nsome proof for age-subordinate deficient penetrance. None of the \npatients conveying transformations had proof of clinical highlights \nof other LRP5-related disease, including bone density or ocular \nabnormalities.\nCLCN7: In light of the closeness between the phenotype of \npatients with childish harmful osteopetrosis (see OPTB4; 611490) \nwhich create serious osteopetrosis and retinal degeneration, \nKornak et al. (2001) hunt down transformations in the human \nCLCN7 gene in 12 patients with juvenile osteopetrosis [144]. They \nrecognized compound heterozygosity for a nonsense (Q555X; \n602727.0001) and a missense (R762Q; 602727.0002) change in the \nCLCN7 quality in 1 persistent with the illness who had early visual \nhindrance. No retinal histology was accessible. Blair et al. (2004) \ndeveloped CD14 cells from control and 4 osteopetrotic human \nsubjects within the sight of bone and analysed their osteoclastic \nseparation in vitro [145]. The osteopetrotic cells indicated absconds \nin acid transport, natural framework evacuation, and cell fusion \nwith inadequate connection compared with the ordinary cells. \nGenotype investigation demonstrated that cells from 2 patients \ncompound heterozygous for TCIRG1 (604592) transformations \nhad acid transport defects, though cells from 1 patient compound \nheterozygous for CLCN7 transformation had natural framework \nevacuation defects. The cells with a connection defect were from \na patient who needed TCIRG1 and CLCN7 transformations. In \naffected people from 12 disconnected families with autosomal \nprevailing osteopetrosis-2 (OPTA2; 166600), Cleiren et al. (2001) \ndistinguished heterozygosity for 7 unique transformations in the \nCLCN7 gene (see, e.g., 602727.0004 and 602727.0005) [146]. \nExamination of microsatellite markers showed that the changes \nemerged autonomously in every family. Among these families was \nthe Danish family that Van Hul et al. (1997) at first connected \nto chromosome 1p21. Also, Cleiren et al. (2001) distinguished \n1 patient with the extreme autosomal recessive puerile type of \nosteopetrosis (OPTB4) who was homozygous for a CLCN7 missense \ntransformation (L766P; 602727.0003), for which her asymptomatic \nguardians were heterozygous [146].\nUROD: In the UROD cDNA from a patient with familial \nporphyria cutanea tarda (PCT; 176100), Garey et al. (1989) showed \na heterozygous gly281-to-val substitution (G281V; 613521.0001). \nThe change was not distinguished in affected people from 7 other \nPCT families with an autosomal dominant pattern of legacy. In \na Tunisian family with hepatoerythropoietic porphyria (HEP; see \n176100), de Verneuil et al. identified homozygosity for a G281E \nchange (613521.0002) in the UROD gene product [147].\nSEMA3A: In 2 sibs and their dad with Kallmann disorder (HH16; \n614897), Young et al. distinguished heterozygosity for a 213-kb \ncancellation in the SEMA3A gene (603961.0001). Sequencing of \nthe nondeleted SEMA3A allele and of 12 known HH-related gene \nin affected individuals from the family did not reveal some other \ntransformations. Youthful et al. reasoned that SEMA3A play a job \nin anosmic hypogonadotropic hypogonadism.\nUSP7: In a 13-year-old young lady with formative deferral, \nhypotonia, and seizures, Hao et al. distinguished a once more \nheterozygous c.429C-G transversion in the USP7 gene, bringing \nabout a tyr143-to-ter (Y143X) substitution and anticipated to result \nin haplo insufficiency. Direct utilitarian investigations of the \nvariation and investigations of patient cells were not performed \n[148]. Be that as it may, in vitro knockdown of USP7 in cells \nbrought about a diminishing in TRIM27 (602165) protein levels \nand impeded endosomal protein reusing with diminished F-actin \ncollection. Hao et al. announced 6 random kids with variable \nneuro developmental issue related with de novo heterozygous \nmicro deletions of chromosome 16p13.2 and 1 patient with a \nnew heterozygous truncating variation in the USP7 gene (602519) \non chromosome 16p13.2. All had formative postponement and \nscholarly incapacity, and 5 were determined to have chemical \nimbalance range issue. Extra regular highlights included seizures (5 \npatients), cryptorchidism or micro penis (in 4 of 5 guys), hypotonia \n(4 patients), and aggressive conduct (4 patients). Different \nhighlights included gentle nonspecific dysmorphic highlights and \npoor or missing speech with speech apraxia. Practically all patients \nwere in a specialized curriculum.\nLTBP3: In affected individuals from a consanguineous Pakistani \nfamily with specific tooth agenesis and short stature (DASS; \n601216), Noor et al. distinguished a homozygous nonsense \ntransformation in the LTBP3 gene (Y744X; 602090.0001). Two \naffected guys were analyzed in detail [149]. The phenotype was \ndescribed by absence of a large number of the perpetual teeth, \njust as obvious expanded bone density in the spine and skull base. \nThe discoveries proposed an essential job for LTBP3-intervened \ntranscription being developed of the axial skeleton. In a mother \nand her 2 children who indicated highlights reliable with mellow \ngeleophysic dysplasia (GPHYSD3; 617809), McInerney-Leo et al. \nrecognized heterozygosity for a missense transformation in the \nLTBP3 gene (S696C; 602090.0008) [150]. In 2 inconsequential \nyoung men determined to have geleophysic dysplasia, who kicked \nthe bucket in early youth from respiratory failure, McInerney-\nLeo et al. recognized heterozygosity for a stop-loss transformation \n(602090.0009) and a splice site transformation (602090.0010) in \nLTBP3, respectively.\nVPS13B: In a 33-year-elderly person who showed the typical facial \ngestalt of Cohen disorder and had neutropenia and retinopathy, \nyet who did not show truncal stoutness or mental impediment, \nGueneau et al. distinguished compound heterozygosity for 2 splice \nsite transformations in the VPS13Bgene (607817.0014; 607817.0015) \n\n8\nDatta S, et al.\nOPEN ACCESS Freely available online\nGene Technol, Vol.9 Iss.2 No:153\n[151]. The authors proposed that a dose impact of remaining \ntypical VPS13B protein may clarify the deficient phenotype in \nthis patient. In 2 Lebanese siblings with Cohen disorder and the \nextra highlights of cutis verticis gyrata and sensorineural deafness, \ninitially announced by Megarbane et al. as an unmistakable \ndisorder, Megarbane et al. recognized a homozygous grafting \ntransformation in the VPS13B gene (607817.0016) [152].\nMNX1: In 2 predominantly acquired sacral agenesis families, \nLynch et al. discovered linkage to 7q36 markers. Ross et al. refined \nthe sub chromosomal confinement in a few extra inherited sacral \nagenesis families and recognized causative transformations in \nthe MNX1 gene (142994.0001-142994.0006) [153]. In affected \nindividuals from a 3-age family isolating Currarino disorder, \nUrioste et al. identified a frameshift transformation in the MNX1 \ngene (142994.0009). Malignant mutation of a presacral teratoma \nwas seen in the 22-year-old proband, and presacral teratomas were \nfound in 6 other relatives, including the 3 asymptomatic people. \nOf 9 influenced individuals, just 2 showed the total set of three. In \naffected individuals from a 4-age family with Currarino disorder, \nWang et al. (2006) recognized heterozygosity for a nonsense \ntransformation in the MNX1 gene (142994.0010) [154].\nADRA1B: The distal end of 5q, 5q31.1-qter, contains the genes for \n2 adrenergic receptors, ADRB2 (109690) and ADRA1B, and the \ndopamine receptor type 1A gene (DRD1A; 126449). Krushkal et \nal. utilized an effective conflicting sib-pair ascertainment plan to \nexamine the effect of this area of the genome on variety in systolic \nblood pressure in youthful Caucasians [155]. They quantified 8 \nexceedingly polymorphic markers crossing this positional applicant \ngene rich district in 427 people from 55 3-age families containing \n69 conflicting sib-pair, and determined multipoint character by \nplunge probabilities. The after effects of hereditary linkage and \naffiliation tests showed that the district between markers D5S2093 \nand D5S462 was altogether connected to at least 1 polymorphic \ngenes influencing inter individual variety in systolic blood pressure. \nSince the ADRA1B and DRD1A genes are found near these \nmarkers, the information recommended that hereditary variety in \n1 or both of these G protein-coupled receptors, which partake in \nthe control of vascular tone, assumes an essential job in affecting \ninter individual variety in systolic blood pressure levels (Table 3). \nGene Name Expression Associated Cancer \n(Mutation Frequency)\nVPS13B\nUbiquitous expression \nin endometrium \n(RPKM 3.0)\nCutaneous melanoma \n(12.47%)\nPLXNA1 Ubiquitous expression \nin lung (RPKM 7.9)\nLung squamous cell \ncarcinoma (5.71%)\nDSCAML1 Biased expression in \nbrain (RPKM 3.3)\nCutaneous melanoma \n(9.76%)\nCDK11A\nUbiquitous expression \nin bone marrow \n(RPKM 22.4)\nCutaneous Melanoma \n(1.08%)\nGLG1 Ubiquitous expression \nin ovary (RPKM 26.0)\nSmall cell lung \ncarcinoma (8.07%)\nLRP5 Ubiquitous expression \nin fat (RPKM 20.9)\nCutaneous melanoma \n(6.78%)\nRABGEF1\nUbiquitous expression \nin bone marrow \n(RPKM 17.2)\nBladder \ncarcinoma(2.04%)\nDENND3\nBroad expression in \nbone marrow (RPKM \n17.0)\nCutaneous melanoma \n(8.40%)\nPRICKLE4 Ubiquitous expression \nin spleen (RPKM 16.5)\nStomach \nadenocarcinoma \n(1.86%)\nSEMA3A Broad expression in \nplacenta (RPKM 2.5)\nBladder carcinoma \n(4.08%)\nSEMA6A Broad expression in \nadrenal (RPKM 13.5)\nLung adenocarcinoma \n(2.56%)\nADRA1B Biased expression in \nspleen (RPKM 2.0)\nStomach \nadenocarcinoma \n(1.86%)\nCLCN7 Ubiquitous expression \nin spleen (RPKM 16.9)\nNon-small cell lung \ncarcinoma (3.23%)\nUSP7 Ubiquitous expression \nin testis (RPKM 31.0)\nStomach \nadenocarcinoma \n(3.73%)\nMFAP3L Broad expression in \nkidney (RPKM 7.1)\nStomach \nadenocarcinoma \n(1.86%)\nL3MBTL1 Broad expression in \ntestis (RPKM 4.3)\nCutaneous melanoma \n(2.17%)\nUROD\nUbiquitous expression \nin bone marrow \n(RPKM 73.9)\nBladder carcinoma \n(1.08%)\nGPR22 Biased expression in \nheart (RPKM 6.9)\nLung adenocarcinoma \n(1.08%)\nATP6V0D2 Biased expression in \nkidney (RPKM 22.7)\nSmall cell lung \ncarcinoma (2.90%)\nZNF274 Ubiquitous expression \nin thyroid (RPKM 9.7)\nCutaneous melanoma \n(2.44%)\nARHGAP40 Biased expression in \nskin (RPKM 12.2)\nAcute myeloid \nleukemia (0.51%)\nLTBP3 Ubiquitous expression \nin ovary (RPKM 27.2)\nCutaneous \nmelanoma(3.25%)\nMNX1 Biased expression in \ncolon (RPKM 3.3)\nLung squamous cell \ncarcinoma(1.15%)\nCEBPB No Data Bladder \ncarcinoma(1.02%)\nASCL2 Broad expression in \ncolon (RPKM 4.3) No Data\nCONCLUSION\nThe investigation can additionally expand in discovering the job \nof such novel genes in interaction and metabolic pathways and \ncan additionally be contemplated for DNA-protein interaction \ninvestigation to help novel research particularly towards its \nmolecular relationship or interaction of the powerful gene products.\nREFERENCES\n1. \nGiudice LC, Kao LC. Endometriosis. Lancet. 2004;364(9447):1789-\n1799. \n2. \nGiudice LC. Clinical practice Endometriosis. N Engl J Med. \n2010;362(25):2389-98. \n3. \nEskenazi B, Warner ML. Epidemiology of endometriosis. \nObstetGynecol Clin North Am. 1997;24(2):235-258. \n4. \nMeuleman C, Vandenabeele B, Fieuws S, Spiessens C, Timmerman \nD, D'Hooghe T. High prevalence of endometriosis in infertile women \nwith normal ovulation and normospermic partners. FertilSteril. \n2009;92(1):68-74.\n5. \nSasson IE, Taylor HS. Stem cells and the pathogenesis of endometriosis. \nTable 3: Novel variants with their expression (taken from gene database \nof NCBI- https://www.ncbi.nlm.nih.gov/gene) and their highest cancer \nassociated mutation frequency (taken from IntOgen- https://www.\nintogen.org/seek).\n\n9\nDatta S, et al.\nOPEN ACCESS Freely available online\nGene Technol, Vol.9 Iss.2 No:153\nAnn N Y Acad Sci. 2008;1127:106-15. \n6. \nAnglesio MS and Yong PJ. Endometriosis-associated Ovarian Cancers. \nClin Obstet Gynecol. 2017;60(4):711-27.\n7. \nAnglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noe M, \nHorlings HM, et al. Cancer-associated mutations in endometriosis \nwithout cancer. N Engl J Med. 2017;376(19):1835-1848.\n8. \nGiudice LC. Clinical practice Endometriosis. N Engl J Med. 2010;362 \n25:2389-98. \n9. \nBerkley KJ, Rapkin AJ, Papka RE. The pains of endometriosis. Science. \n2005;308(5728):1587-1589. \n10. \nTokushige N, Markham R, Russell P, Fraser IS. Nerve fibres in \nperitoneal endometriosis. Hum Reprod. 2006;21(11):3001-3007. \n11. \nBulun SE. Endometriosis. N Engl J Med. 2009;360(3):268-79.\n12. \nSourial S, Tempest N, Hapangama DK. Theories on the pathogenesis \nof endometriosis. Int J Reprod Med. 2014;2014:179515.\n13. \nRobboy SJ, Bean SM. Pathogenesis of endometriosis. Reprod Biomed \nOnline. 2010;21(1):4-5. \n14. \nRobboy SJ, Haney AF, Russell P. Endometriosis. In: Robboy, SJ, \nMutter, GL, Prat, J, Bentley, RC, Russell, P, Anderson, MC (Eds), \nPathology of the Female Reproductive Tract, second ed. London: \nChurchill Livingstone. 2009.\n15. \nSomigliana E, Vigano P, Parazzini F, Stoppelli S, Giambattista \nE, Vercellini P. Association between endometriosis and cancer: \na comprehensive review and a critical analysis of clinical and \nepidemiological evidence. GynecolOncol. 2006;101(2):331-41. \n16. \nPavone ME, Lyttle BM. Endometriosis and ovarian cancer: links, risks, \nand challenges faced. Int J Womens Health. 2015;7:663-72.\n17. \nOverton C, Shaw RW, McMillan L, Davis C. Atlas of Endometriosis, \n3rd Edition. CRC Press; 2007.\n18. \nNoe M, Ayhan A, Wang TL, Shih IM. Independent development of \nendometrial epithelium and stroma within the same endometriosis. J \nPathol. 2018;245 3:265-9. \n19. \nSampson JA. Endometrial carcinoma of the ovary, arising in \nendometrial tissue in that organ. Archives of Surgery. 1925;10:1-72.\n20. \nCzernobilsky B, Morris WJ. A histologic study of ovarian endometriosis \nwith emphasis on hyperplastic and atypical changes. Obstet Gynecol. \n1979;53:250-253.\n21. \nTai FW, Chang CY, Chiang JH, Lin WC, Wan L. Association \nof Pelvic Inflammatory Disease with Risk of Endometriosis: A \nNationwide Cohort Study Involving 141,460 Individuals. J Clin Med. \n2018;7(11):35-39.\n22. \nFigueira PG, Abrao MS, Krikun G, Taylor HS. Stem cells in \nendometrium and their role in the pathogenesis of endometriosis. \nAnn N Y Acad Sci. 2011;1221:10-7.\n23. \nDarrow SL, Vena JE, Batt RE, Michalek AM, Selman S. Menstrual \ncycle characteristics and the risk of endometriosis. Epidemiology. \n1993;4(2):135–142. \n24. \nSignorello LB, Harlow BL, Cramer DW. Epidemiologic determinants \nof endometriosis: a hospital-based case-control study. Ann Epidemiol. \n1997;7(4):267-741. \n25. \nCramer DW, Missmer SA. The epidemiology of endometriosis. Ann N \nY Acad Sci. 2002;955:11-22. \n26. \nCandiani GB, Danesino V, Gastaldi A, Ferraroni M. Reproductive and \nmenstrual factors and risk of peritoneal and ovarian endometriosis. \nFertilSteril. 1991;56(2):230-234. \n27. \nKvaskoff M, Bijon A, Clavel-Chapelon F. Childhood and adolescent \nexposures and the risk of endometriosis. Epidemiology. 2013;24(2):261-\n269. \n28. \nMatalliotakis IM, Arici A, Cakmak H. Familial aggregation of \nendometriosis in the yale series. Arch Gynecol Obstet. 2008;278(6):507-\n511. \n29. \nTreloar SA, O’Connor DT. Genetic influences on endometriosis in an \nAustralian twin sample. FertilSteril. 1999;71(4):701-710. \n30. \nRahmioglu N, Nyholt DR, Morris AP. Genetic variants underlying \nrisk of endomStriosis: insights from meta-analysis of eight genome-\nwide association and replication datasets. Hum Reprod Update. \n2014;20(5):702-716. \n31. \nNyholt DR, Low SK, Anderson CA. Genome-wide association \nmeta-analysis identifies new endometriosis risk loci. Nat Genet. \n2012;44(12):1355-1359. \n32. \nJaaskelainen M, Prunskaite-Hyyrylainen R, Naillat F, et al. WNT4 is \nexpressed in human fetal and adult ovaries and its signaling contributes \nto ovarian cell survival. Mol Cell Endocrinol. 2010;317(1-2):106-111. \n33. \nVainio S, Heikkila M, Kispert A. Female development in mammals is \nregulated by Wnt-4 signalling. Nature. 1999;397(6718):405-409.\n34. \nBoyer A, Lapointe E, Zheng X, Cowan RG, Li H, Quirk SM, et al. \nWNT4 is required for normal ovarian follicle development and female \nfertility. FASEB J. 2010;24(8):3010-3025. \n35. \nGuo X, Jing C, Li L. Down-regulation of VEZT gene expression in \nhuman gastric cancer involves promoter methylation and miR-43c. \nBiochem Biophys Res Commun. 2011;404(2):622-627. \n36. \nRae JM, Johnson MD, Scheys JO. GREB 1 is a critical regulator of \nhormone dependent breast cancer growth. Breast Cancer Res Treat. \n2005;92(2):141-149. \n37. \nGhosh MG, Thompson DA, Weigel RJ. PDZK1 and GREB1 are \nestrogen-regulated genes expressed in hormone-responsive breast \ncancer. Cancer Res. 2000;60(22):6367-6375. \n38. \nAlbertsen HM, Chettier R, Farrington P, Ward K. Genome-wide \nassociation study link novel loci to endometriosis. PLoS One. \n2013;8(3):e58257. \n39. \nUno S, Zembutsu H, Hirasawa A. A genome-wide association study \nidentifies genetic variants in the CDKN2BAS locus associated with \nendometriosis in Japanese. Nat Genet. 2010;42(8):707-710. \n40. \nPainter JN, Anderson CA, Nyholt DR. Genome-wide association \nstudy identifies a locus at 7p15.2 associated with endometriosis. Nat \nGenet. 2011;43(1):51-54. \n41. \nUimari O, Rahmioglu N, Nyholt DR. Genome-wide genetic analyses \nhighlight mitogen-activated protein kinase (MAPK) signaling in the \npathogenesis of endometriosis. Hum Reprod. 2017;32(4):780-793. \n42. \nSapkota Y, Steinthorsdottir V, Morris AP. Meta-analysis identifies \nfive novel loci associated with endometriosis highlighting key genes \ninvolved in hormone metabolism. Nat Commun. 2017;8:15539. \n43. \nFung JN, Rogers PA, Montgomery GW. Identifying the biological basis \nof GWAS hits for endometriosis. Biol Reprod. 2015;92(4):87. \n44. \nBerker B, Seval M. Problems with the diagnosis of endometriosis. \nWomens Health (Lond). 2015;11(5):597-601.\n45. \nMoss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical \npractice. J Clin Pathol. 2005;58(3):308-312. \n46. \nHuhtinen K, Suvitie P, Hiissa J. Serum HE4 concentration \ndifferentiates malignant ovarian tumours from ovarian endometriotic \ncysts. Br J Cancer. 2009;100(8):1315-1319. \n47. \nLeyland N, Casper R, Laberge P. Endometriosis: diagnosis and \nmanagement. J ObstetGynaecol Can. 2010;32(7):S1–32.\n48. \nWykes CB, Clark TJ, Khan KS. Accuracy of laparoscopy in the \ndiagnosis of endometriosis: a systematic quantitative review. BJOG. \n2004;111(11):1204-1212. \n49. \nHori Y, Committee SG. Diagnostic laparoscopy guidelines:this \nguideline was prepared by the SAGES guidelines committee and \nreviewed and approved by the Board of Governors of the society \nof American gastrointestinal and endoscopic surgeons (SAGES), \nNovember 2007. Surg Endosc. 2008;22(5):1353-1383. \n50. \nBurney RO, Giudice LC. Pathogenesis and pathophysiology of \nendometriosis. FertilSteril. 2012;98(3):511-519. \n\n10\nDatta S, et al.\nOPEN ACCESS Freely available online\nGene Technol, Vol.9 Iss.2 No:153\n51. \nRogers PA, D’Hooghe TM, Fazleabas A. Defining future directions \nfor endometriosis research: workshop report from the 2011 World \nCongress of Endometriosis in Montpellier, France. Reprod Sci. \n2013;20(5):483-499. \n52. \nBurghaus S, Haberle L, Schrauder MG. Endometriosis as a risk factor \nfor ovarian or endometrial cancer-results of a hospital-based case-\ncontrol study. BMC Cancer. 2015;15:751. \n53. \nWykes CB, Clark TJ, Chakravati S. Efficacy of laparoscopic excision of \nvisually diagnosed peritoneal endometriosis in the treatment of chronic \npelvic pain. Eur J ObstetGynecol Reprod Biol. 2006;125(1):129-133. \n54. \nBedaiwy MA, Alfaraj S, Yong P, Casper R, et al. New developments in \nthe medical treatment of endometriosis. FertilSteril. 2017;107(3):555-\n565. \n55. \nStreuli I, de Ziegler D, Borghese B. New treatment strategies and \nemerging drugs in endometriosis. Expert Opin Emerg Drugs. \n2012;17(1):83-104. \n56. \nBukulmez O, Hardy DB, Carr BR, Word RA, Mendelson CR. \nInflammatory status influences aromatase and steroid receptor \nexpression in endometriosis. Endocrinology. 2008;149(3):1190–1204. \n57. \nHan SJ, O’Malley BW. The dynamics of nuclear receptors and nuclear \nreceptor coregulators in the pathogenesis of endometriosis. Hum \nReprod Update. 2014;20(4):467-484. \n58. \nGuo SW. Epigenetics of endometriosis. Mol Hum Reprod. \n2009;15(10):587-607. \n59. \nKobayashi H, Yamada Y, Kanayama S. The role of iron in the \npathogenesis of endometriosis. Gynecol Endocrinol. 2009;25(1):39-\n52.\n60. \nVercellini P, Crosignani P, Somigliana E. The ‘incessant menstruation’ \nhypothesis: a mechanistic ovarian cancer model with implications for \nprevention. Hum Reprod. 2011;26(9):2262-2273. \n61. \nToyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic \ndisease. Cancer Sci. 2009;100(1):9-16. \n62. \nOta H, Igarashi S, Sasaki M. Distribution of cyclooxygenase-2 in \neutopic and ectopic endometrium in endometriosis and adenomyosis. \nHum Reprod. 2001;16(3):561-566.\n63. \nLin YJ, Lai MD, Lei HY. Neutrophils and macrophages promote \nangiogenesis in the early stage of endometriosis in a mouse model. \nEndocrinology. 2006;147(3):1278-1286. \n64. \nAhn SH, Edwards AK, Singh SS, Young SL, Lessey BA, Tayade C. \nIL-17A contributes to the pathogenesis of endometriosis by triggering \nproinflammatory cytokines and angiogenic growth factors. J Immunol. \n2015;195(6):2591-2600. \n65. \nZhang X, Xu H, Lin J. Peritoneal fluid concentrations of interleukin-17 \ncorrelate with the severity of endometriosis and infertility of this \ndisorder. BJOG. 2005;112(8):1153-1155. \n66. \nMcKinnon BD, Bertschi D, Bersinger NA. Inflammation and nerve \nfiber interaction in endometriotic pain. Trends Endocrinol Metab. \n2015;26(1):1-10. \n67. \nWorley MJ, Welch WR, Berkowitz RS. Endometriosis-associated \novarian cancer: a review of pathogenesis. Int J Mol Sci. 2013;14(3):5367-\n5379. \n68. \nBrinton LA, Sakoda LC, Sherman ME, Frederiksen K, Kjaer SK, \nGraubard BI, et al. Relationship of benign gynecologic diseases to \nsubsequent risk of ovarian and uterine tumors. Cancer Epidemiol \nBiomarkers Prev. 2005;1412:2929-35. \n69. \nRossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, \nWeiss NS. Risk of epithelial ovarian cancer in relation to benign \novarian conditions and ovarian surgery. Cancer Causes Control. \n2008;19(10):1357-64.\n70. \nForte A, Cipollaro M, Galderisi U. Genetic, epigenetic and stem cell \nalterations in endometriosis: new insights and potential therapeutic \nperspectives. Clin Sci (Lond). 2014;126 2:123-38. \n71. \nNezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in the \npathophysiology of ovarian cancer and implications for screening and \nprevention. Am J Obstet Gynecol. 2015;213(3):262-7.\n72. \nKvaskoff M, Mu F, Terry KL, Harris HR, Poole EM, Farland L, et \nal. Endometriosis: a high-risk population for major chronic diseases? \nHum Reprod Update. 2015;21 4:500-16.\n73. \nPearce CL, Templeman C, Rossing MA. Association between \nendometriosis and risk of histological subtypes of ovarian cancer: a \npooled analysis of case-control studies. Lancet Oncol. 2012;13(4):385-\n394.\n74. \nMatalliotakis M, Matalliotaki C, Goulielmos GN, Patelarou E, Tzardi \nM, Spandidos DA, et al. Association between ovarian cancer and \nadvanced endometriosis. OncolLett. 2018;15(5):7689-92. \n75. \nKok VC, Tsai HJ, Su CF, Lee CK. The Risks for Ovarian, Endometrial, \nBreast, Colorectal, and Other Cancers in Women With Newly \nDiagnosed Endometriosis or Adenomyosis: A Population-Based Study. \nInt J Gynecol Cancer. 2015;25 6:968-76. \n76. \nDawson A, Fernandez ML, Anglesio M, Yong PJ, Carey MS. \nEndometriosis and endometriosis-associated cancers: new insights \ninto the molecular mechanisms of ovarian cancer development. \nEcancermedicalscience. 2018;12:803. \n77. \nOda K, Hamanishi J, Matsuo K , Hasegawa K. Genomics to \nimmunotherapy of ovarian clear cell carcinoma: Unique opportunities \nfor management. GynecolOncol. 2018;151(2):381-9.\n78. \nZondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Vigano \nP. Endometriosis. Nat Rev Dis Primers. 2018;4(1):9.\n79. \nSampson JA. Metastatic or embolic endometriosis, due to the menstrual \ndissemination of endometrial tissue into the venous circulation. Am J \nPathol. 1927;3(2):93-110. \n80. \nVercellini P, Crosignani P, Somigliana E. The ‘incessant menstruation’ \nhypothesis: a mechanistic ovarian cancer model with implications for \nprevention. Hum Reprod. 2011;26(9):2262-2273. \n81. \nLaGrenade A, Silverberg SG. Ovarian tumors associated with atypical \nendometriosis. Hum Pathol. 1988;19(9):1080-1084. \n82. \nFukunaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical \nendometriosis: its close association with malignant epithelial tumours. \nHistopathology. 1997;30(3):249-255. \n83. \nJiang X, Morland SJ, Hitchcock A. Allelotyping of endometriosis with \nadjacent ovarian carcinoma reveals evidence of a common lineage. \nCancer Res. 1998;58(8):1707-1712. \n84. \nScott RB. Malignant changes in endometriosis. Obstet Gynecol. \n1953;2(3):283-289. \n85. \nLu Y, Cuellar-Partida G, Painter JN. Shared genetics underlying \nepidemiological association between endometriosis and ovarian \ncancer. Hum Mol Genet. 2015;24(20):5955–5964. \n86. \nProwse AH, Manek S, Varma R. Molecular genetic evidence that \nendometriosis is a precursor of ovarian cancer. Int J Cancer. \n2006;119(3):556-562. \n87. \nMcMeekin DS, Burger RA, Manetta A. Endometrioid adenocarcinoma \nof the ovary and its relationship to endometriosis. GynecolOncol. \n1995;59(1):81-86. \n88. \nSainz de la Cuesta R, Eichhorn JH, Rice LW, et al. Histologic \ntransformation of benign endometriosis to early epithelial ovarian \ncancer. GynecolOncol. 1996;60(2):238–244. \n89. \nWorley MJ Jr, Liu S, Hua Y. Molecular changes in endometriosis-\nassociated ovarian clear cell carcinoma. Eur J Cancer. 2015;51(13):1831-\n1842. \n90. \nSato N, Tsunoda H, Nishida M. Loss of heterozygosity on 10q23.3 and \nmutation of the tumor suppressor gene PTEN in benign endometrial \ncyst of the ovary: possible sequence progression from benign \nendometrial cyst to endometrioid carcinoma and clear cell carcinoma \nof the ovary. Cancer Res. 2000;60(24):7052-7056. \n91. \nStamp JP, Gilks CB, Wesseling M. BAF250a expression in atypical \nendometriosis and endometriosis-associated ovarian cancer. Int J \nGynecol Cancer. 2016;26(5):825-832.\n\n11\nDatta S, et al.\nOPEN ACCESS Freely available online\nGene Technol, Vol.9 Iss.2 No:153\n92. \nAnglesio MS, Bashashati A, Wang YK, Senz J, Ha G, Yang W, et al. \nMultifocal endometriotic lesions associated with cancer are clonal and \ncarry a high mutation burden. J Pathol. 2015;236(2):201-209.\n93. \nWiegand KC, Shah SP, Al-Agha OM. ARID1A mutations in \nendometriosis-associated ovarian carcinomas. N Engl J Med. \n2010;363(16):1532-1543. \n94. \nChene G, Ouellet V, Rahimi K, Barres V, Provencher D, Mes-Masson \nAM. The ARID1A pathway in ovarian clear cell and endometrioid \ncarcinoma, contiguous endometriosis, and benign endometriosis. Int \nJ Gynaecol Obstet. 2015;130(1):27-30. \n95. \nBischoff FZ, Heard M, Simpson JL. Somatic DNA alterations in \nendometriosis: high frequency of chromosome 17 and p53 loss in late-\nstage endometriosis. J Reprod Immunol. 2002;55(1-2):49-64. \n96. \nSainz de la Cuesta R, Izquierdo M, Canamero M. Increased prevalence \nof p53 overexpression from typical endometriosis to atypical \nendometriosis and ovarian cancer associated with endometriosis. Eur \nJ ObstetGynecol Reprod Biol. 2004;113(1):87-93. \n97. \nVestergaard AL, Thorup K, Knudsen UB. Oncogenic events associated \nwith endometrial and ovarian cancers are rare in endometriosis. Mol \nHum Reprod. 2011;17(12):758-761. \n98. \nLaudanski P, Szamatowicz J, Kowalczuk O. Expression of selected \ntumor suppressor and oncogenes in endometrium of women with \nendometriosis. Hum Reprod. 2009;24(8):1880-1890. \n99. \nYamamoto S, Tsuda H, Takano M. PIK3CA mutation is an early event \nin the development of endometriosis-associated ovarian clear cell \nadenocarcinoma. J Pathol. 2011;225(2):189-194. \n100. \nGrassi T, Calcagno A, Marzinotto S. Mismatch repair system in \nendometriotic tissue and eutopic endometrium of unaffected women. \nInt J Clin Exp Pathol. 2015;8(2):1867-1877. \n101. \nFuseya C, Horiuchi A, Hayashi A, et al. Involvement of pelvic \ninflammation-related mismatch repair abnormalities and microsatellite \ninstability in the malignant transformation of ovarian endometriosis. \nHum Pathol. 2012;43(11):1964-1972. \n102. \nYang W, Zhang Y, Fu F. High-resolution array-comparative \ngenomic hybridization profiling reveals 20q13.33 alterations associated \nwith ovarian endometriosis. Gynecol Endocrinol. 2013;29(6):603-607. \n103. \nMafra F, Mazzotti D, Pellegrino R. Copy number variation \nanalysis reveals additional variants contributing to endometriosis \ndevelopment. J Assist Reprod Genet. 2016;34(1):117-124. \n104. \nAli-Fehmi R, Khalifeh I, Bandyopadhyay S, Lawrence WD, \nSilva E, Liao D, et al. Patterns of loss of heterozygosity at 10q23.3 \nand microsatellite instability in endometriosis, atypical endometriosis, \nand ovarian carcinoma arising in association with endometriosis. Int J \nGynecol Pathol. 2006;25(3):223-229. \n105. \nXu B, Hamada S, Kusuki I. Possible involvement of loss of \nheterozygosity in malignant transformation of ovarian endometriosis. \nGynecolOncol. 2011;120(2):239-246. \n106. \nObata K, Hoshiai H. Common genetic changes between \nendometriosis and ovarian cancer. GynecolObstet Invest. \n2000;50(S1):39-43. \n107. \nThomas EJ, Campbell IG. Molecular genetic defects in \nendometriosis. GynecolObstet Invest. 2000;50(S1):44-50. \n108. \nSilveira CG, Abrao MS, Dias JA. Common chromosomal \nimbalances and stemness-related protein expression markers in \nendometriotic lesions from different anatomical sites: the potential \nrole of stem cells. Hum Reprod. 2012;27(11):3187-3197. \n109. \nLee AW, Templeman C, Stram DA. Evidence of a genetic link \nbetween endometriosis and ovarian cancer. FertilSteril. 2015;105(1):35-\n43. \n110. \nYamamoto S, Tsuda H, Takano M. Loss of ARID1A protein \nexpression occurs as an early event in ovarian clear-cell carcinoma \ndevelopment and frequently coexists with PIK3CA mutations. Mod \nPathol. 2012;25(4):615-624. \n111. \nWu RC, Wang TL, Shih Ie M. The emerging roles of ARID1A \nin tumor suppression. Cancer Biol Ther. 2014;15(6):655-664. \n112. \nNishikimi K, Kiyokawa T, Tate S. ARID1A expression in \novarian clear cell carcinoma with an adenofibromatous component. \nHistopathology. 2015;67(6):866-871. \n113. \nGuan B, Rahmanto YS, Wu RC, et al. Roles of deletion of \nArid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J Natl \nCancer Inst. 2014;106(7):146. \n114. \nBorrelli GM, Abrao MS, Taube ET, Darb-Esfahani S, Köhler C, \nChiantera V, et al. (Partial) Loss of BAF250a (ARID1A) in rectovaginal \ndeep-infiltrating endometriosis, endometriomas and involved pelvic \nsentinel lymph nodes. Mol Hum Reprod. 2016;22(5):329-337. \n115. \nTomasetti C, Vogelstein B. Cancer etiology. variation in cancer \nrisk among tissues can be explained by the number of stem cell \ndivisions. Science. 2015;347(6217):78-81.\n116. \nKatagiri A, Nakayama K, Rahman MT. Loss of ARID1A \nexpression is related to shorter progression-free survival and \nchemoresistance in ovarian clear cell carcinoma. Mod Pathol. \n2012;25(2):282–288. \n117. \nLowery WJ, Schildkraut JM, Akushevich L. Loss of ARID1A-\nassociated protein expression is a frequent event in clear cell and \nendometrioid ovarian cancers. Int J Gynecol Cancer. 2012;22(1):9-14. \n118. \nWiegand KC, Hennessy BT, Leung S. A functional \nproteogenomic analysis of endometrioid and clear cell carcinomas \nusing reverse phase protein array and mutation analysis: protein \nexpression is histotype-specific and loss of ARID1A/BAF250a is \nassociated with AKT phosphorylation. BMC Cancer. 2014;14:120.\n119. \nMinlikeeva AN, Freudenheim JL, Eng KH. History of \ncomorbidities and survival of ovarian cancer patients, results from the \novarian cancer association consortium. Cancer Epidemiol Biomarkers \nPrev. 2017;26(9):1470-1473. \n120. \nMeldrum C, Doyle MA, Tothill RW. Next-generation sequencing \nfor cancer diagnostics: a practical perspective. Clin Biochem Rev. \n2011;32(4):177-95.\n121. \nEvans T, Matulonis U. Next-Generation Sequencing: Role in \nGynecologic Cancers. J Natl ComprCanc Netw. 2016;14(9):1165-73.\n122. \nValtcheva N, Lang FM, Noske A, Samartzis EP, Schmidt AM, \nBellini E, et al. Tracking the origin of simultaneous endometrial and \novarian cancer by next-generation sequencing-a case report. BMC \nCancer. 2017;17:25-27.\n123. \nMorash M, Mitchell H, Beltran H, Elemento O, Pathak J. The \nRole of Next-Generation Sequencing in Precision Medicine: A Review \nof Outcomes in Oncology. J Pers Med. 2018;8(3):24-29.\n124. \nFountzilas E, Tsimberidou AM. Overview of precision oncology \ntrials: challenges and opportunities. Expert Rev Clin Pharmacol. \n2018;11 8:797-804.\n125. \nEr TK, Su YF, Wu CC, Chen CC, Wang J, Hsieh TH, et \nal. Targeted next-generation sequencing for molecular diagnosis \nof endometriosis-associated ovarian cancer. J Mol Med (Berl). \n2016;94(7):835-47.\n126. \nLi X, Zhang Y, Zhao L, Wang L, Wu Z, Mei Q, et al. Whole-\nexome sequencing of endometriosis identifies frequent alterations in \ngenes involved in cell adhesion and chromatin-remodeling complexes. \nHum Mol Genet. 2014;23(22):6008-21. \n127. \nSuda K, Nakaoka H, Yoshihara K, Ishiguro T, Tamura R, Mori \nY, et al. Clonal Expansion and Diversification of Cancer-Associated \nMutations in Endometriosis and Normal Endometrium. Cell Rep. \n2018;24(7):1777-89.\n128. \nLac V, Verhoef L, Aguirre-Hernandez R, Nazeran TM, Tessier-\nCloutier B, Praetorius T, et al. Iatrogenic endometriosis harbors \nsomatic cancer-driver mutations. Hum Reprod. 2018.\n129. \nGoss M, James R, Caleb E Finch, Morgan DG. Age-Related \nChanges in Glial Fibrillary Acidic Protein Mrna in the Mouse Brain. \nNeurobiology of aging 1991;12(2):165-170. \n130. \nNichols A, Nancy R, Day JR, Laping NJ, Johnson SA, Finch CE. \n\n12\nDatta S, et al.\nOPEN ACCESS Freely available online\nGene Technol, Vol.9 Iss.2 No:153\nGfapMrna Increases with Age in Rat and Human Brain. Neurobiology \nof aging. 1993;14(5):421-429. \n131. \nLangmead B, Salzberg, SL. Fast gapped-read alignment with \nBowtie 2. Nat Methods. 2012;9(4):357-359. \n132. \nLi H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et \nal. Genome Project Data Processing S. 2009.\n133. \nBlankenberg D, Gordon A, Von Kuster G, Coraor N, Taylor \nJ, Nekrutenko A, et al. Manipulation of Fastq Data with Galaxy. \nBioinformatics. 2010.\n134. \nBlankenberg, D, Kuster GV, Coraor N, Ananda G, Lazarus R, \nMangan M, et al. Galaxy: A Web-Based Genome Analysis Tool for \nExperimentalists. In Current Protocols in Molecular Biology: John \nWiley & Sons, Inc., 2001. \n135. \nGoecks JA. Nekrutenko, J. Taylor. Galaxy: A Comprehensive \nApproach for Supporting Accessible, Reproducible, and Transparent \nComputational Research in the Life Sciences. Genome Biol. \n2010;11(8):R86. \n136. \nSherry A, Stephen T, Ward M-H, M Kholodov, J Baker, Lon \nPhan, et al. Dbsnp: The Ncbi Database of Genetic Variation. Nucl acid \nres. 2001;29(1):308-311. \n137. \nAndrews S. Fastqc a Quality Control Tool for High Throughput \nSequence Data. \n138. \nWang K, M Li, Hakonarson H. ANNOVAR: functional \nannotation of genetic variants from high-throughput sequencing data. \nNuc Acid Res, 2010;38(16):e164.\n139. \nGong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, \nReginato AM, et al. LDL receptor-related protein 5 (LRP5) affects \nbone accrual and eye development. Cell. 2001;107:513-523.\n140. \nLittle RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, \nFolz C, et al. A mutation in the LDL receptor-related protein 5 gene \nresults in the autosomal dominant high-bone-mass trait. Am. J. Hum. \nGenet. 2002;70:11-19.\n141. \nBoyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, \net al. High bone density due to a mutation in LDL-receptor-related \nprotein 5. New Eng J Med. 2002;346:1513-1521. \n142. \nGuo X, Jing C, Li L. Down-regulation of VEZT gene expression \nin human gastric cancer involves promoter methylation and miR-43c. \nBiochem Biophys Res Commun. 2011;404(2):622-627. \n143. \nCnossen WR, teMorsche RHM, Hoischen A, Gilissen C, \nChrispijn M, Venselaar H, et al. Whole-exome sequencing reveals \nLRP5 mutations and canonical Wntsignaling associated with hepatic \ncystogenesis. Proc. Nat. Acad. Sci. 2014;111:5343-5348.\n144. \nKornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, \net al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice \nand man. Cell. 2001;104:205-215.\n145. \nBlair HC, Borysenko CW, Villa A, Schlesinger PH, Kalla SE, \nYaroslavsky BB, et al. In vitro differentiation of CD14 cells from \nosteopetrotic subjects: contrasting phenotypes with TCIRG1, CLCN7, \nand attachment defects. J Bone Miner Res. 2004;19:1329-1338.\n146. \nCleiren E, Benichou O, Van Hul E, Gram J, Bollerslav J, Singer \nFR, et al. Albers-Schonberg disease (autosomal dominant osteopetrosis, \ntype II) results from mutations in the ClCN7 chloride channel gene. \nHum Molec Genet. 2001;10:2861-2867.\n147. \nde Verneuil H, Hansen J, Picat C, Grandchamp B, Kushner \nJ, Roberts A, et al. Prevalence of the 281 (gly-to-glu) mutation in \nhepatoerythropoietic porphyria and porphyria cutaneatarda. Hum \nGenet. 1988;78:101-102.\n148. \nHaoY-H, Fountain MD, Tacer F, Xia K, Bi F, Kang W, et al. USP7 \nacts as a molecular rheostat to promote WASH-dependent endosomal \nprotein recycling and is mutated in a human neurodevelopmental \ndisorder. Molec Cell. 2015;59:956-969.\n149. \nNoor A, Windpassinger C, Vitcu I, Orlic M, Rafiq MA, Khalid \nM, et al. Oligodontia is caused by mutation in LTBP3, the gene \nencoding latent TGF-beta binding protein 3. Am J Hum Genet. \n2009;84:519-523.\n150. \nMcInerney-Leo AM, Le Goff C, Leo PJ, Kenna TJ, Keith P, \nHarris JE, et al. Mutations in LTBP3 cause acromicric dysplasia and \ngeleophysic dysplasia. J Med Genet. 2012.\n151. \nGueneau L, Duplomb L, Sarda P, Hamel C, Aral B, El Chehadeh \nS, et al. Congenital neutropenia with retinopathy, a new phenotype \nwithout intellectual deficiency or obesity secondary to VPS13B \nmutations. Am J Med Genet. 2014;164A:522-527.\n152. \nMegarbane A, Waked N, Chouery E, Moglabey YB, Saliba N, \nMornet E, et al. Microcephaly, cutis verticisgyrata of the scalp, retinitis \npigmentosa, cataracts, sensorineural deafness, and mental retardation \nin two brothers. Am J Med Genet. 2001;98: 244-249.\n153. \nRoss AJ, Ruiz-Perez V, Wang Y, Hagan D-M, Scherer S, Lynch \nSA, et al. Homeobox gene, HLXB9, is the major locus for dominantly \ninherited sacral agenesis. Nature Genet. 1998;20:358-361. \n154. \nWang RY, Jones JR, Chen S, Rogers RC, Friez MJ, Schwartz \nCE, et al. A previously unreported mutation in a Currarino syndrome \nkindred. Am J Med Genet. 2006;140A:1923-1930. \n155. \nKrushkal J, Xiong M, Ferrell R, Sing CF, Turne, ST, Boerwinkle \nE. Linkage and association of adrenergic and dopamine receptor genes \nin the distal portion of the long arm of chromosome 5 with systolic \nblood pressure variation. Hum Molec Genet. 1998;7:1379-1383.","source_license":"CC0","license_restricted":false}